- Home
- SVRA vs AMLX Comparison
SVRA vs AMLX Comparison
Compare SVRA & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- AMLX
- Stock Information
- Founded
- SVRA N/A
- AMLX 2014
- Country
- SVRA United States
- AMLX United States
- Employees
- SVRA N/A
- AMLX N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- AMLX Health Care
- Exchange
- SVRA Nasdaq
- AMLX Nasdaq
- Market Cap
- SVRA 458.2M
- AMLX 481.9M
- IPO Year
- SVRA N/A
- AMLX 2022
- Fundamental
- Price
- SVRA $2.85
- AMLX $3.62
- Analyst Decision
- SVRA Buy
- AMLX Buy
- Analyst Count
- SVRA 7
- AMLX 7
- Target Price
- SVRA $9.86
- AMLX $7.60
- AVG Volume (30 Days)
- SVRA 1.0M
- AMLX 976.8K
- Earning Date
- SVRA 03-06-2025
- AMLX 02-20-2025
- Dividend Yield
- SVRA N/A
- AMLX N/A
- EPS Growth
- SVRA N/A
- AMLX N/A
- EPS
- SVRA N/A
- AMLX N/A
- Revenue
- SVRA N/A
- AMLX $196,485,000.00
- Revenue This Year
- SVRA N/A
- AMLX N/A
- Revenue Next Year
- SVRA N/A
- AMLX N/A
- P/E Ratio
- SVRA N/A
- AMLX N/A
- Revenue Growth
- SVRA N/A
- AMLX N/A
- 52 Week Low
- SVRA $2.59
- AMLX $1.58
- 52 Week High
- SVRA $5.70
- AMLX $19.95
- Technical
- Relative Strength Index (RSI)
- SVRA 45.63
- AMLX 47.23
- Support Level
- SVRA $2.62
- AMLX $3.21
- Resistance Level
- SVRA $2.88
- AMLX $3.75
- Average True Range (ATR)
- SVRA 0.19
- AMLX 0.26
- MACD
- SVRA 0.02
- AMLX 0.05
- Stochastic Oscillator
- SVRA 40.37
- AMLX 79.69
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.